<unk>  is a kinase inhibitor that is FDA approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) that has progressed on or is intolerant to crizotinib.   Common adverse reactions include nausea, diarrhea, fatigue, cough, and headache.
Brigatinib
Fostamatinib
Neratinib
Lenvatinib
Dasatinib
Lorlatinib
Enasidenib
Afatinib